IMPORTANT CORRECTION: April 23, 2021
Several recent news stories incorrectly reported that IES Life Sciences has applied for and is awaiting Emergency Use Approval for its COVID-19 Severity test. Although the company plans to do so in the near future, IES Life Sciences has not yet applied to the FDA for Emergency Use Approval for its test.
IES Life Sciences, Inc. is an Innovative, Precision Diagnostics Company with patented technology that interrogates the human immune system to improve diagnosis and treatment of traditionally hard-to-diagnose diseases at their earliest stages.
Learn more about our current patented technology
“IES’s business model aspires to improve early, effective diagnosis for a number of medical ailments based on licensed technology from the NIH. The combination of a plausible business model and a management team with significant investment of personal commitment, financial resources, and passion seems, to me, the right combination of elements to make IES a solid investment thesis.”
"I was afflicted and impacted by Lupus. It took over 4 years to figure out what was happening. With the IES technology, it is probable that I could have been diagnosed quickly and would have received appropriate treatment much sooner. Additionally, I would not have wasted time going from doctor to doctor trying to determine what was wrong. Early diagnosis is beneficial to all concerned. "
THE IES APPROACH
The body’s earliest response to infections/diseases is to make cellular proteins called interferons, commonly referred to as "IFNs". IFNs are present in most diseases and viruses and each virus/disease produces a unique set of the 21 different IFNs (the “IFN Signature”). IES has co-developed, with leading FDA scientists, the first and only
comprehensive test to accurately and reliably identify the IFN Signature for a disease. IES’s patented technology (U.S. Patent 9,193995) can detect and diagnose a wide variety of traditionally DIFFICULT to diagnose diseases, at the earliest possible stage, with a simple blood test. In addition, the test can be used as the cornerstone for the development of targeted therapeutics that attack diseases by regulating the immune system.
MULTITUDE OF APPLICATIONS
There are a multitude of opportunities for the development of diagnostics for other autoimmune diseases with significant diagnostic challenges including Lyme, MS and Rheumatoid Arthritis. Our initial target is Lupus. In addition, because IES can identify contagious diseases immediately following exposure with a simple blood test, the technology has significant national security and military applications. In the event of an outbreak of a disease of unknown origin, the IES test can be deployed to quickly and reliably identify the source of the outbreak, accelerating response times and significantly aiding in containing and combatting the outbreak. Because the test can identify a virus or disease immediately following exposure, the test can be used to screen troops deployed to an area with a contagious outbreak, rapidly identifying infected individuals, providing for early intervention and eliminate the need for prolonged quarantines of the entire deployment.
OUR FIRST TARGET: LUPUS
SLE accounts for more than 77,000 annual US hospital admissions
Average stay of 10 days
Given the large patient population, the difficulty in diagnosis and the substantial benefits of early diagnosis, IES has chosen to initially focus on Lupus SLE. Because the symptoms of Lupus masquerade as a number of other diseases, a definitive diagnosis is extremely challenging, lengthy and costly. Misdiagnosis and late diagnosis are two fundamental reasons why Lupus is so damaging. It can take four to six years or more for a definitive diagnosis. While early diagnosis has been proven to dramatically increase patient outcomes, delayed diagnosis compromises organs resulting in serious and often life-threatening complications. An early stage diagnostic blood test will dramatically reduce the time between initial symptoms and diagnosis, resulting in dramatically better patient outcomes and substantial healthcare savings.
THE BENEFITS OF THE IES TEST DO NOT STOP
AT INITIAL DIAGNOSIS.
ADDITIONAL USES INCLUDE:
Defining Treatment - As expensive, powerful new therapeutics are developed to help treat Lupus, the IES test will be used to stratify patients, identifying the subset of Lupus patients that will actually benefit from the treatment. This will prevent patients who will not benefit from receiving unnecessary and potentially dangerous treatment and will, at the same time, save payers from having to pay for an expensive * treatment that will not work on a particular patient.
Treatment Monitoring - Once the patient that will benefit from the drug is identified, the IES test will be used on an ongoing basis (approximately four times a year) to monitor the effectiveness of treatment and make adjustments accordingly.
* Anifrolumab, the first new Lupus SLE therapeutic in years, is expected to receive FDA approval later this year and is estimated to cost $100,000 a year.